Published in Obstet Gynecol on March 01, 1987
Current chemotherapeutic management of patients with gestational trophoblastic neoplasia. Chemother Res Pract (2011) 1.06
Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer (2003) 0.94
Metastatic intracerebral choriocarcinoma in a teenager. J Natl Med Assoc (1997) 0.80
Inhibin: a new circulating marker of hydatidiform mole? BMJ (1989) 0.75
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 5.56
A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst (2001) 2.83
The role of cervical cytology in the declining morbidity and mortality of cervical cancer. Cancer (1974) 2.70
Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst (1983) 2.57
The relation of endometriosis to menstrual characteristics, smoking, and exercise. JAMA (1986) 2.22
Tubal infertility and the intrauterine device. N Engl J Med (1985) 2.22
Failure of methotrexate treatment for term placenta percreta. Am J Obstet Gynecol (1994) 2.05
Ultrasonographically guided subclavian vein catheterization in critical care obstetrics and gynecologic oncology. Am J Obstet Gynecol (1993) 2.05
Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol (2001) 1.96
Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res (1993) 1.89
Chorionic tumors. N Engl J Med (1996) 1.87
Incidence and histopathology of malignancies of the female genital organs in the United States. Am J Obstet Gynecol (1974) 1.86
Prevalence and predictors of depressive symptoms in older premenopausal women: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry (1999) 1.78
SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol (2001) 1.76
Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst (1983) 1.71
Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst (1998) 1.64
Are caffeinated beverages risk factors for delayed conception? Lancet (1990) 1.62
Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors. Cancer Res (2001) 1.61
Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst (2000) 1.59
Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer (2011) 1.56
Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res (1995) 1.56
Body mass index and ovulatory infertility. Epidemiology (1994) 1.55
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54
Five years' experience with the prevention of trophoblastic tumors by the prophylactic use of chemotherapy in patients with molar pregnancy. Clin Obstet Gynecol (1970) 1.53
The influence of lactose consumption on the association of oral contraceptive use and ovarian cancer risk. Am J Epidemiol (1991) 1.52
Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol (1993) 1.52
Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol (1994) 1.48
Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum. Hum Pathol (2000) 1.48
Fertility and use of cigarettes, alcohol, marijuana, and cocaine. Ann Epidemiol (1993) 1.47
The changing clinical presentation of complete molar pregnancy. Obstet Gynecol (1995) 1.47
Outcome of pregnancies occurring before completion of human chorionic gonadotropin follow-up in patients with persistent gestational trophoblastic tumor. Gynecol Oncol (1999) 1.44
Natural history of twin pregnancy with complete hydatidiform mole and coexisting fetus. Obstet Gynecol (1994) 1.43
SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene (1996) 1.42
Relation of tubal infertility to history of sexually transmitted diseases. Am J Epidemiol (1993) 1.38
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer (2008) 1.38
Laparoscopy in the diagnosis and management of pelvic pain in adolescents. J Reprod Med (1980) 1.37
Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer (2001) 1.37
Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol (2000) 1.35
Prospective study of talc use and ovarian cancer. J Natl Cancer Inst (2000) 1.28
Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer (1975) 1.27
Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer (1999) 1.26
DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene (1998) 1.26
Early follicular phase hormone levels in relation to patterns of alcohol, tobacco, and coffee use. Fertil Steril (2001) 1.23
Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology (1998) 1.23
Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol (2000) 1.22
The chemotherapy of gestational trophoblastic disease: principles of clinical management. JAMA (1972) 1.21
DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene (1998) 1.20
Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol (2000) 1.19
Ovarian cancer and talc: a case-control study. Cancer (1982) 1.19
Invasive cervical carcinoma in young women. Gynecol Oncol (1979) 1.17
A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer. Oncogene (1996) 1.16
Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol (1997) 1.16
Gonadal mosaicism and genetic counseling for X-linked recessive lethals. Am J Hum Genet (1974) 1.14
Infertility in women and moderate alcohol use. Am J Public Health (1994) 1.14
Epidemiologic determinants of endometriosis: a hospital-based case-control study. Ann Epidemiol (1997) 1.12
Clinical features of multiple conception with partial or complete molar pregnancy and coexisting fetuses. J Reprod Med (1994) 1.12
Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res (2001) 1.11
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol (2001) 1.10
The relationship of tubal infertility to barrier method and oral contraceptive use. JAMA (1987) 1.09
Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol (1986) 1.09
Central nervous system involvement by ovarian carcinoma: a complication of prolonged survivial with metastatic disease. Cancer (1978) 1.09
Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. Int J Cancer (2000) 1.08
A flow cytometric study of 137 fresh hydropic placentas: correlation between types of hydatidiform moles and nuclear DNA ploidy. Obstet Gynecol (1992) 1.07
Gestational trophoblastic disease. Subsequent pregnancy outcome, including repeat molar pregnancy. J Reprod Med (1998) 1.07
Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med (1982) 1.06
Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod (2013) 1.06
Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res (1996) 1.05
Ethnic background and in vitro fertilization outcomes. Int J Gynaecol Obstet (2005) 1.05
A new human topoisomerase III that interacts with SGS1 protein. Nucleic Acids Res (1999) 1.05
Dietary animal fat in relation to ovarian cancer risk. Obstet Gynecol (1984) 1.04
Sonographic diagnosis of partial hydatidiform mole. Obstet Gynecol (1989) 1.02
Gestational trophoblastic disease of the fallopian tube. J Reprod Med (1991) 1.02
Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res (1995) 1.02
The clinical application of a specific radioimmunoassay for human chorionic gondotropin in trophoblastic and nontrophoblastic tumors. Surg Gynecol Obstet (1974) 1.02
Predictive value of serum and follicular fluid leptin concentrations during assisted reproductive cycles in normal women and in women with the polycystic ovarian syndrome. Hum Reprod (2000) 1.01
Statistical methods in evaluating the outcome of infertility therapy. Fertil Steril (1979) 1.01
Natural history of partial molar pregnancy. Obstet Gynecol (1985) 1.01
Prophylactic chemotherapy of patients with molar pregnancy. Obstet Gynecol (1971) 1.01
Maternal exposure to second-hand tobacco smoke and pregnancy outcome among couples undergoing assisted reproduction. Hum Reprod (2006) 1.01
Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol (1992) 1.01